Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2026-526494-42-00
Authorised, not yet recruiting Phase II

Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer

2026-526494-42-00 · tracked via the Priya Life Science EU tracker
Sponsor
Varsinais-Suomen hyvinvointialue
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Neoplasms
Decision date
05/06/2026
Enrollment target
80
Sites
Finland

Condition studied

Gastric cancer

Investigational medicinal product(s)

[18F]FAPI-74

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

The primary variable of this study is to demonstrate the detection rates of the primary tumor, metastatic lymph nodes and distant metastases in gastric cancer with 18F-FAPI-74 PET/CT

Endpoint detail

Secondary variable is to demonstrate the detection of distant metastases with 18F-FAPI-74 PET/CT. PET findings are compared to the gold standard of histopathological findings, or in recurrent disease to histopathological findings or routine clinical follow-up CT in one year.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526494-42-00 on CTIS ↗ ← All trials in the EU